It has been revealed that inhibiting the rapamycin-insensitive companion of the mammalian target of rapamycin (RICTOR) as a mTORC2 component, as well as inhibition of mTORC1, mTORC2, and PI3K, could remarkably interrupt the progression of pancreatic cancer and prolong survival in end-stage of the tumor [78]. This evidence concerns the gene MTOR and neoplasm.